期刊文献+

上皮性卵巢癌患者2种肿瘤细胞减灭术治疗的临床比较

下载PDF
导出
摘要 目的:对比2种肿瘤细胞减灭术治疗上皮性卵巢癌(Epithelial Ovarian Cancer,EOC)患者的效果。方法:选取2019年1月-2020年1月郑州人民医院106例EOC患者,按随机数字表法分为对照组(n=53)和观察组(n=53)。对照组行初始肿瘤细胞减灭术(Primary debulking surgery,PDS)后接受6个周期辅助化疗;观察组行PDS手术后接受3个周期辅助化疗,然后再行间歇性肿瘤细胞减灭术(Interval debulking surgery,IDS)手术后化疗3个周期。比较两组疾病控制率及肿瘤标志物水平,记录并比较两组术后并发症。结果:观察组疾病控制率高于对照组(P<0.05);辅助化疗结束时,两组人类附睾蛋白4(Human epididymal protein 4,HE4)、糖类抗原125(Carbohydrate antigen 125,CA125)、糖类抗原199(Carbohydrate antigen 199,CA199)、甲胎蛋白(Alpha fetoprotein,AFP)水平均降低,且观察组变化较大(P<0.05);两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:与PDS相比,IDS治疗EOC可有效提高疾病控制率,降低肿瘤标志物水平。
作者 曹士红
出处 《四川生理科学杂志》 2022年第1期135-137,共3页 Sichuan Journal of Physiological Sciences
  • 相关文献

参考文献10

二级参考文献42

  • 1Lahlou N,Brun JL. Ovarian tumor markers of presumed benign o varian tumors[J].J Gynecol Obstet Biol Reprod (Paris), 2013,42 (8):752.
  • 2Peng D,Xu T,Mason TJ,et al. A study of ovarian cancer biomar- ker amplification using ultrasound for early stage detection[J]. Ultrasonics, 2014,54 (2) :451.
  • 3Freydanck MK, Laubender RP, Rack B, et al. Two-marker combi- nations for preoperative discrimination of benign and malignant o- varian masses[J]. Anticancer Res, 2012,32 (5) : 2003.
  • 4Donach M,Yu Y,Artioli G,et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women[J]. Tumour Biol, 2010,31(3) :209.
  • 5Vallius T,Hynninen J,Auranen A,et al. Serum HE4 and CA125 as predictors of response and outcome during neoadiuvant chemo- therapy of advanced high-grade serous ovarian cancer[J]. Turnout Biol,2014,35(12) :12389.
  • 6Cho HY,Kim K,Jeon YT,et al. CA19-9 elevation in ovarian ma- ture cystic teratoma:discrimination from ovarian cancer - CA19-9 level in teratomal-J]. Med Sei Monit, 2013,19 : 230.
  • 7Nolen BM,Brand RE, Prosser D, et al. Prediagnostic serum bio- markers as early detection tools for pancreatic cancer in a large prospective cohort study[J]. PLoS One, 2014,9(4) : e94928.
  • 8Milman S, Whitney KD, Fleischer N. Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125[J]. Thyroid, 2011 ;21(8) :913.
  • 9Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer[J]. J Ovarian Res, 2014,7 : 62.
  • 10Karlan BY,Thorpe J,Watabayashi K,et al. Use of CA125 and HFA se- rum markers to predict ovarian cancer in elevated-risk women[J]. Cancer Epidemiol Biomarkers Prey,2014,23(7):1383.

共引文献510

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部